Zentiva's Zent2U Claims Advantage On EU Entresto Entry
B2B Unit Looks To Filing And Launch After Bioequivalence Study Success
Zentiva’s Zent2U B2B unit says that it will be ready to register for a European generic version of Novartis’ Entresto immediately upon data exclusivity expiry, putting its version in position for a “day one” launch once intellectual property protecting the cardiovascular blockbuster expires.
You may also be interested in...
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.
Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.
The FTC has won the backing of an appeals court over its 2019 decision that found a reverse-payment settlement deal between Impax and Endo over Opana ER to be anti-competitive and illegal.